MT-ND4 and optic atrophy: Taurine is thus a promising metabolite for future studies on its involvement in FD retinal pathology and may be a good candidate metabolite for therapeutic interventions focused on mitigating the progressive optic atrophy observed in FD patients, as well as that of LHON and DOA.